Cytokinetics Company Leadership
| CYTK Stock | USD 49.35 1.68 3.52% |
Cytokinetics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Cytokinetics suggests that most insiders are panicking. Cytokinetics employs about 423 people. The company is managed by 19 executives with a total tenure of roughly 37 years, averaging almost 1.0 years of service per executive, having 22.26 employees per reported executive.
| Robert Blum CEO CEO and President Director and Chief Executive of the Biopharmaceutical Concern |
| Robert Wong President Chief Accounting Officer, Vice President |
Cytokinetics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-11-18 | Robert I Blum | Disposed 5000 @ 50.55 | View | ||
| 2024-11-12 | Fady Ibraham Malik | Disposed 6342 @ 58.48 | View | ||
| 2024-11-01 | Robert I Blum | Disposed 5000 @ 51.63 | View | ||
| 2024-10-30 | Fady Ibraham Malik | Disposed 7300 @ 51.91 | View | ||
| 2024-10-28 | Wendall Wierenga | Disposed 4452 @ 52.25 | View | ||
| 2024-10-15 | Fady Ibraham Malik | Disposed 7300 @ 54.19 | View | ||
| 2024-10-09 | Robert I Blum | Disposed 5000 @ 55.61 | View | ||
| 2024-10-01 | Fady Ibraham Malik | Disposed 7300 @ 52.1 | View | ||
| 2024-09-30 | Robert I Blum | Disposed 5000 @ 52.14 | View | ||
| 2024-09-03 | Fady Ibraham Malik | Disposed 7384 @ 57.01 | View | ||
| 2024-08-12 | B Lynne Parshall | Disposed 5000 @ 55.2 | View | ||
| 2024-08-06 | Fady Ibraham Malik | Disposed 7300 @ 53.71 | View | ||
| 2024-07-30 | Robert I Blum | Disposed 11500 @ 59.49 | View | ||
| 2024-07-29 | B Lynne Parshall | Disposed 5000 @ 59.84 | View | ||
| 2024-07-23 | Fady Ibraham Malik | Disposed 7300 @ 57.02 | View | ||
| 2024-07-15 | B Lynne Parshall | Disposed 5000 @ 55.82 | View | ||
| 2024-07-10 | Robert I Blum | Disposed 11500 @ 54.29 | View | ||
| 2024-07-09 | Fady Ibraham Malik | Disposed 7300 @ 55.9 | View |
Monitoring Cytokinetics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Cytokinetics |
Cytokinetics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Cytokinetics' future performance. Based on our forecasts, it is anticipated that Cytokinetics will maintain a workforce of about 420 employees by December 2024.Cytokinetics Management Team Effectiveness
The company has return on total asset (ROA) of (0.3013) % which means that it has lost $0.3013 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.7215) %, meaning that it created substantial loss on money invested by shareholders. Cytokinetics' management efficiency ratios could be used to measure how well Cytokinetics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 1.43 this year, although the value of Return On Tangible Assets will most likely fall to (0.67). At this time, Cytokinetics' Liabilities And Stockholders Equity is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 1.2 B this year, although the value of Non Current Liabilities Other will most likely fall to about 338.3 M.Common Stock Shares Outstanding is expected to rise to about 101.4 M this year, although the value of Net Loss is projected to rise to (332.6 M).
Cytokinetics Workforce Comparison
Cytokinetics is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,026. Cytokinetics totals roughly 423 in number of employees claiming about 41% of equities under Health Care industry.
Cytokinetics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytokinetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytokinetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cytokinetics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 0.65 | 13 | 20 | 41,765 | 88,346 |
| 2024-09-01 | 0.5682 | 25 | 44 | 190,818 | 240,660 |
| 2024-06-01 | 1.0 | 24 | 24 | 225,502 | 209,056 |
| 2024-03-01 | 0.931 | 27 | 29 | 353,531 | 339,524 |
| 2023-12-01 | 0.7368 | 14 | 19 | 95,798 | 185,478 |
| 2023-09-01 | 0.7619 | 16 | 21 | 83,339 | 149,141 |
| 2023-06-01 | 1.8235 | 31 | 17 | 210,537 | 155,619 |
| 2023-03-01 | 0.8056 | 29 | 36 | 633,588 | 272,193 |
| 2022-12-01 | 0.7778 | 14 | 18 | 82,674 | 163,918 |
| 2022-09-01 | 0.5854 | 24 | 41 | 165,548 | 429,036 |
| 2022-06-01 | 1.4545 | 32 | 22 | 246,512 | 277,270 |
| 2022-03-01 | 1.1622 | 43 | 37 | 621,894 | 390,947 |
| 2021-12-01 | 0.7391 | 34 | 46 | 288,115 | 480,120 |
| 2021-09-01 | 0.8519 | 23 | 27 | 45,552 | 115,474 |
| 2021-06-01 | 0.9787 | 46 | 47 | 243,078 | 211,072 |
| 2021-03-01 | 0.9556 | 43 | 45 | 925,092 | 376,517 |
| 2020-12-01 | 0.4211 | 24 | 57 | 222,910 | 787,397 |
| 2020-09-01 | 0.4857 | 17 | 35 | 111,510 | 210,969 |
| 2020-06-01 | 0.7111 | 32 | 45 | 307,646 | 276,849 |
| 2020-03-01 | 1.9375 | 31 | 16 | 860,479 | 1,151,503 |
| 2019-12-01 | 0.7778 | 7 | 9 | 348,072 | 22,500 |
| 2019-06-01 | 1.5 | 9 | 6 | 180,000 | 60,500 |
| 2019-03-01 | 4.75 | 19 | 4 | 773,824 | 8,500 |
| 2018-06-01 | 0.8889 | 8 | 9 | 160,000 | 65,000 |
| 2018-03-01 | 2.1333 | 32 | 15 | 828,433 | 51,355 |
| 2017-12-01 | 0.1507 | 11 | 73 | 24,604 | 64,366 |
| 2017-09-01 | 0.2404 | 25 | 104 | 158,099 | 217,316 |
| 2017-06-01 | 0.9 | 9 | 10 | 215,000 | 5,000 |
| 2017-03-01 | 4.625 | 37 | 8 | 751,974 | 61,995 |
| 2016-06-01 | 3.5 | 7 | 2 | 155,000 | 30,000 |
| 2016-03-01 | 4.75 | 19 | 4 | 696,875 | 70,000 |
| 2015-03-01 | 2.0 | 20 | 10 | 571,555 | 103,750 |
| 2014-03-01 | 4.5 | 18 | 4 | 1,036,381 | 60,000 |
| 2013-09-01 | 0.5 | 5 | 10 | 85,414 | 117,506 |
| 2013-06-01 | 2.0 | 8 | 4 | 203,782 | 49,998 |
| 2012-09-01 | 0.5 | 5 | 10 | 512,500 | 700,234 |
| 2012-06-01 | 1.3333 | 8 | 6 | 191,447 | 4,372,099 |
| 2011-03-01 | 6.0 | 18 | 3 | 1,366,388 | 25,000 |
| 2010-06-01 | 0.2292 | 11 | 48 | 210,000 | 1,188,601 |
| 2010-03-01 | 1.3529 | 23 | 17 | 865,716 | 40,998 |
| 2009-12-01 | 0.1935 | 18 | 93 | 304,146 | 573,096 |
| 2009-09-01 | 0.1915 | 9 | 47 | 67,000 | 146,000 |
| 2009-06-01 | 0.2817 | 20 | 71 | 2,459,402 | 173,200 |
| 2009-03-01 | 0.6757 | 25 | 37 | 1,025,566 | 79,570 |
| 2008-09-01 | 0.1667 | 8 | 48 | 56,162 | 117,170 |
| 2008-06-01 | 3.5 | 7 | 2 | 120,000 | 2,000 |
| 2008-03-01 | 1.7778 | 16 | 9 | 933,134 | 12,634 |
| 2007-12-01 | 0.1818 | 8 | 44 | 57,172 | 123,344 |
| 2007-09-01 | 0.3871 | 12 | 31 | 119,246 | 155,684 |
| 2007-06-01 | 0.3636 | 16 | 44 | 139,500 | 88,674 |
| 2007-03-01 | 0.4634 | 19 | 41 | 642,299 | 44,200 |
| 2006-12-01 | 0.1857 | 13 | 70 | 66,000 | 141,600 |
| 2006-09-01 | 0.1935 | 12 | 62 | 60,996 | 129,592 |
| 2006-06-01 | 0.2929 | 29 | 99 | 133,892 | 181,484 |
| 2006-03-01 | 0.85 | 34 | 40 | 594,013 | 84,026 |
| 2005-12-01 | 0.2571 | 27 | 105 | 141,800 | 175,000 |
| 2005-06-01 | 8.0 | 16 | 2 | 286,500 | 31,000 |
| 2005-03-01 | 0.6667 | 2 | 3 | 80,000 | 20,000 |
| 2004-12-01 | 1.7778 | 16 | 9 | 170,000 | 1,715,715 |
| 2004-06-01 | 0.5167 | 31 | 60 | 26,338,817 | 38,593,877 |
Cytokinetics Notable Stakeholders
A Cytokinetics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cytokinetics often face trade-offs trying to please all of them. Cytokinetics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cytokinetics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Robert Blum | CEO and President Director and Chief Executive of the Biopharmaceutical Concern | Profile | |
| Robert Wong | Chief Accounting Officer, Vice President | Profile | |
| Ching Jaw | CFO, Senior Vice President | Profile | |
| Sung Lee | Executive CFO | Profile | |
| John Esq | Associate VP | Profile | |
| Andrew Callos | Executive Officer | Profile | |
| Jeff Lotz | Vice Operations | Profile | |
| Steven Cook | Senior Operations | Profile | |
| Scott Jordan | Senior Strategy | Profile | |
| FACC MD | Ex RD | Profile | |
| Eric Terhaerdt | Senior Operations | Profile | |
| YulyMae DiNapoli | Vice Resources | Profile | |
| Matt Yang | Vice Analysis | Profile | |
| Steven JD | Senior Operations | Profile | |
| James Spudich | CoFounder Board | Profile | |
| Joanna Siegall | Associate Relations | Profile | |
| Stuart MD | Senior Officer | Profile | |
| Kari JD | VP Officer | Profile | |
| Diane Weiser | IR Contact Officer | Profile |
About Cytokinetics Management Performance
The success or failure of an entity such as Cytokinetics often depends on how effective the management is. Cytokinetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cytokinetics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cytokinetics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (0.69) | (0.65) | |
| Return On Assets | (0.64) | (0.67) | |
| Return On Equity | 1.36 | 1.43 |
Cytokinetics Workforce Analysis
Traditionally, organizations such as Cytokinetics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cytokinetics within its industry.Cytokinetics Manpower Efficiency
Return on Cytokinetics Manpower
| Revenue Per Employee | 17.8K | |
| Revenue Per Executive | 396.3K | |
| Net Loss Per Employee | 1.2M | |
| Net Loss Per Executive | 27.7M | |
| Working Capital Per Employee | 1.2M | |
| Working Capital Per Executive | 27.7M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share 0.03 | Quarterly Revenue Growth 0.225 | Return On Assets (0.30) | Return On Equity (5.72) |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.